The latest price target for Enfusion (NYSE:ENFN) was reported by Stifel on December 18, 2024. The analyst firm set a price target for $13.00 expecting ENFN to rise to within 12 months (a possible 22.29% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Enfusion (NYSE:ENFN) was provided by Stifel, and Enfusion maintained their buy rating.

The last upgrade for Enfusion Inc happened on January 3, 2023 when Morgan Stanley raised their price target to $12. Morgan Stanley previously had an equal-weight for Enfusion Inc.

The last downgrade for Enfusion Inc happened on February 28, 2024 when Goldman Sachs changed their price target from $9 to $8 for Enfusion Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enfusion, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enfusion was filed on December 18, 2024 so you should expect the next rating to be made available sometime around December 18, 2025.

While ratings are subjective and will change, the latest Enfusion (ENFN) rating was a maintained with a price target of $11.00 to $13.00. The current price Enfusion (ENFN) is trading at is $10.63, which is out of the analyst’s predicted range.